AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1429339 — intervention group
Group type: COMPARATOR
Intervention: Contemporaneous control group treated conventionally.
Number of subjects: 91
Study 1429339 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 91
Study 1429339 — intervention group
Group type: COMPARATOR
Intervention: Contemporaneous control group
Number of subjects: 91
Study 644633 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses providing family planning services
Number of subjects: 0
Study 644633 — intervention group
Group type: COMPARATOR
Intervention: Physicians providing family planning services
Number of subjects: 0
Study 31552815 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori IgG antibody sero-prevalence among Arabs
Number of subjects: 1651
Study 31552815 — intervention group
Group type: COMPARATOR
Intervention: H. pylori IgG antibody sero-prevalence among Jews
Number of subjects: 1651
Study 31552815 — intervention group
Group type: EXPERIMENTAL
Intervention: CagA IgG antibody sero-positivity among H. pylori positives in Arabs
Number of subjects: 1651
Study 31552815 — intervention group
Group type: COMPARATOR
Intervention: CagA IgG antibody sero-positivity among H. pylori positives in Jews
Number of subjects: 1651
Study 27718262 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulobuterol patch (TP)
Number of subjects: 33
Study 27718262 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol inhaler (SA)
Number of subjects: 33
Study 24948413 — intervention group
Group type: EXPERIMENTAL
Intervention: Perhexiline
Number of subjects: 286
Study 24948413 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 286
Study 24943857 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg (2 mL) dexketoprofen
Number of subjects: 50
Study 24943857 — intervention group
Group type: COMPARATOR
Intervention: 2 mL normal saline (control)
Number of subjects: 50
Study 22070862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 40
Study 22070862 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 40
Study 22070862 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-responders)
Number of subjects: 40
Study 20014650 — intervention group
Group type: EXPERIMENTAL
Intervention: Start unstable condition (high instability along the first half of the trajectory decreasing as the target was approached)
Number of subjects: 0
Study 20014650 — intervention group
Group type: EXPERIMENTAL
Intervention: End unstable condition (instability increasing along the first half of the trajectory and remaining high as the target was approached)
Number of subjects: 0
Study 20014650 — intervention group
Group type: COMPARATOR
Intervention: Null field condition (neutral stability everywhere)
Number of subjects: 0
Study 20014650 — intervention group
Group type: COMPARATOR
Intervention: End unstable condition
Number of subjects: 0
Study 17317393 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30
Study 17317393 — intervention group
Group type: COMPARATOR
Intervention: Ketamine
Number of subjects: 30
Study 15451743 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive-lifestyle intervention
Number of subjects: 152
Study 15451743 — intervention group
Group type: EXPERIMENTAL
Intervention: Reimbursable-lifestyle intervention
Number of subjects: 152
Study 15451743 — intervention group
Group type: COMPARATOR
Intervention: Usual-care
Number of subjects: 152
Study 15451743 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including usual-care)
Number of subjects: 152
Study 11391126 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg entacapone
Number of subjects: 25
Study 11391126 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg entacapone
Number of subjects: 25
Study 11391126 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg entacapone
Number of subjects: 25
Study 11391126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9679843 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (50 or 100 microg twice daily)
Number of subjects: 325
Study 9679843 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (100 microg twice daily)
Number of subjects: 325
Study 9679843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 7982173 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 (intratumoral injection)
Number of subjects: 395
Study 7982173 — intervention group
Group type: COMPARATOR
Intervention: Control (no injection)
Number of subjects: 395
Study 2512765 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 mcg
Number of subjects: 3
Study 2512765 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 400 mcg
Number of subjects: 3
Study 2512765 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 800 mcg
Number of subjects: 3
Study 2512765 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 3
Study 2512765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 30231121 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (24-week program)
Number of subjects: 35
Study 30231121 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard pharmacological treatment)
Number of subjects: 35
Study 26089103 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided rendezvous (EUS-RV)
Number of subjects: 20
Study 24809448 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa/Carbidopa treatment for patients with low DβH activity genotypes (CT/TT)
Number of subjects: 71
Study 24809448 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for patients with low DβH activity genotypes (CT/TT)
Number of subjects: 71
Study 24809448 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa/Carbidopa treatment for patients with normal DβH activity genotype (CC)
Number of subjects: 71
Study 22322214 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheostomy (ET)
Number of subjects: 100
Study 19663753 — intervention group
Group type: EXPERIMENTAL
Intervention: Web site intervention based on social cognitive theory (SCT)
Number of subjects: 91
Study 19663753 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 91
Study 19020325 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy
Number of subjects: 377
Study 19020325 — intervention group
Group type: COMPARATOR
Intervention: Deferred antiretroviral therapy
Number of subjects: 377
Study 15821274 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide mixed with short-acting insulin
Number of subjects: 51
Study 15821274 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide mixed with long-acting insulin
Number of subjects: 51
Study 15821274 — intervention group
Group type: COMPARATOR
Intervention: Separate injections of pramlintide and insulin
Number of subjects: 51
Study 15821274 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide and insulin mixtures
Number of subjects: 51
Study 15821274 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 51
Study 12052589 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop electrosurgical excision procedure during luteal phase
Number of subjects: 60
Study 12052589 — intervention group
Group type: COMPARATOR
Intervention: Loop electrosurgical excision procedure during follicular phase
Number of subjects: 60
Study 10391163 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 10 ml through a subcutaneous catheter
Number of subjects: 104
Study 10391163 — intervention group
Group type: COMPARATOR
Intervention: Dipyrone 500 mg orally
Number of subjects: 104
Study 8871418 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 79
Study 8871418 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy plus family management (CBT + FAM)
Number of subjects: 79
Study 8871418 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (Control)
Number of subjects: 79
Study 8871418 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment effectiveness
Number of subjects: 79
Study 8871418 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT vs CBT + FAM
Number of subjects: 79
Study 8871418 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and gender interaction
Number of subjects: 79
Study 1637600 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 MAC isoflurane
Number of subjects: 10
Study 1637600 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 MAC isoflurane
Number of subjects: 10
Study 1637600 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 MAC isoflurane
Number of subjects: 10
Study 1637600 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MAC isoflurane
Number of subjects: 10
Study 1637600 — intervention group
Group type: COMPARATOR
Intervention: 0 MAC isoflurane (control)
Number of subjects: 10
Study 1637600 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane administration
Number of subjects: 10
Study 6207648 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethambutol (20 mg/kg bodyweight/day) with streptomycin and isoniazid (SHE)
Number of subjects: 134
Study 6207648 — intervention group
Group type: COMPARATOR
Intervention: Streptomycin, isoniazid and thioacetazone (SHT)
Number of subjects: 134
Study 11863299 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation 1 (150 mg)
Number of subjects: 6
Study 11863299 — intervention group
Group type: COMPARATOR
Intervention: Formulation 2 (150 mg)
Number of subjects: 6
Study 29913374 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (12 months)
Number of subjects: 1631
Study 27977585 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physical‐, cognitive‐, and mindfulness training (PCMT)
Number of subjects: 112
Study 27977585 — intervention group
Group type: COMPARATOR
Intervention: Reference group (control)
Number of subjects: 112
Study 25456363 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfav-dose-dense group
Number of subjects: 263
Study 25456363 — intervention group
Group type: COMPARATOR
Intervention: Unfav-BEP group
Number of subjects: 263
Study 25456363 — intervention group
Group type: EXPERIMENTAL
Intervention: Fav-BEP group
Number of subjects: 263
Study 23064478 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (onabotulinumtoxinA; 140-200 units) injections into the pectoralis major with or without injections to the teres major
Number of subjects: 37
Study 23064478 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) injections
Number of subjects: 37
Study 23064478 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (onabotulinumtoxinA; 140-200 units) injections
Number of subjects: 37
Study 20103445 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous regimen of ethinylestradiol (30 mcg) and drospirenone (3 mg) for 168 days
Number of subjects: 78
Study 20103445 — intervention group
Group type: COMPARATOR
Intervention: Traditional cyclic regimen of ethinylestradiol (30 mcg) and drospirenone (3 mg) for six 28-day cycles with a 7-day hormone-free interval
Number of subjects: 78
Study 18806012 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevidipine (CLV)
Number of subjects: 1512
Study 18806012 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 1512
Study 15694572 — intervention group
Group type: EXPERIMENTAL
Intervention: Single course of hylan G-F 20
Number of subjects: 255
Study 15694572 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat course of hylan G-F 20
Number of subjects: 255
Study 15694572 — intervention group
Group type: COMPARATOR
Intervention: Appropriate care without hylan G-F 20
Number of subjects: 255
Study 12706743 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of diethyl carbamazine citrate (DEC)
Number of subjects: 29
Study 12706743 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 day treatment with diethyl carbamazine citrate (DEC)
Number of subjects: 29
Study 12706743 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-endemic area)
Number of subjects: 29
Study 10361567 — intervention group
Group type: EXPERIMENTAL
Intervention: Version M (mainstream drug - Metoprolol)
Number of subjects: 291
Study 10361567 — intervention group
Group type: COMPARATOR
Intervention: Version V (unconventional drug - beef spleen cell extract)
Number of subjects: 291
Study 10150847 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal eye drops
Number of subjects: 0
Study 10150847 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal agents
Number of subjects: 0
Study 1827622 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg orally for 6 days)
Number of subjects: 6
Study 1827622 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (14.8 mg intravenously)
Number of subjects: 6
Study 1827622 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic models
Number of subjects: 6
Study 7280443 — intervention group
Group type: EXPERIMENTAL
Intervention: Octavalent vaccine (serotypes 1, 3, 6A, 7F, 14, 18C, 19F, and 23F)
Number of subjects: 124
Study 7280443 — intervention group
Group type: COMPARATOR
Intervention: Heptavalent control vaccine (serotypes 2, 4, 5, 8, 9N, 12F, and 24F)
Number of subjects: 124
Study 7280443 — intervention group
Group type: EXPERIMENTAL
Intervention: Octavalent vaccine
Number of subjects: 124
Study 7280443 — intervention group
Group type: COMPARATOR
Intervention: Heptavalent control vaccine
Number of subjects: 124
Study 30912314 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-appropriate reusable Masimo probe with Masimo Rad-87 box (M + M)
Number of subjects: 572
Study 30912314 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifebox LB-01 probe with Masimo Rad-87 box (L + M)
Number of subjects: 572
Study 30912314 — intervention group
Group type: COMPARATOR
Intervention: Lifebox LB-01 probe and Lifebox V1.5 box (L + L)
Number of subjects: 572
Study 28073339 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm & Hammer™ Sensitive Skin plus Skin‐Friendly Fresh Scent
Number of subjects: 0
Study 28073339 — intervention group
Group type: COMPARATOR
Intervention: Arm & Hammer Free & Clear
Number of subjects: 0
Study 26555595 — intervention group
Group type: EXPERIMENTAL
Intervention: MFO intensity training
Number of subjects: 136
Study 26555595 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% of VO2-peak intensity training
Number of subjects: 136
Study 26555595 — intervention group
Group type: EXPERIMENTAL
Intervention: Free moderate-intensity at-home exercise
Number of subjects: 136
Study 26555595 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 136
Study 23320544 — intervention group
Group type: EXPERIMENTAL
Intervention: Spice burger (cooked with salt and spice mix)
Number of subjects: 22
Study 23320544 — intervention group
Group type: COMPARATOR
Intervention: Control burger (cooked with salt only)
Number of subjects: 22
Study 20720438 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with PDR
Number of subjects: 30
Study 20720438 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with poor glycemic control
Number of subjects: 30
Study 20720438 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PDR receiving panretinal photocoagulation (PRP)
Number of subjects: 30
Study 20720438 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 30
Study 20720438 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 30
Study 19117896 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP(5)‐IPV‐Hib
Number of subjects: 1939
Study 19117896 — intervention group
Group type: COMPARATOR
Intervention: Separate vaccines (DTaP(5), IPV, Hib)
Number of subjects: 1939
Study 17503745 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) associated with atazanavir/ritonavir
Number of subjects: 53
Study 15214256 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine-fortified wheat flour
Number of subjects: 80
Study 15214256 — intervention group
Group type: COMPARATOR
Intervention: Non-fortified wheat flour
Number of subjects: 80
Study 12479506 — intervention group
Group type: EXPERIMENTAL
Intervention: TCDD exposure (mean serum concentration between 2.6 and 8.1 ppt)
Number of subjects: 37
Study 10731737 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 104
Study 10731737 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 104
Study 9618132 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic pancreatic therapy
Number of subjects: 0
Study 9618132 — intervention group
Group type: COMPARATOR
Intervention: Surgical techniques
Number of subjects: 0
Study 1895044 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (E), 20 mg d‐1
Number of subjects: 22
Study 1895044 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (E), 40 mg d‐1
Number of subjects: 22
Study 1895044 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release verapamil (V), 240 mg d‐1
Number of subjects: 22
Study 1895044 — intervention group
Group type: COMPARATOR
Intervention: Quality-of-life questionnaire
Number of subjects: 22
Study 6193353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous isosorbide dinitrate infusion (50-200 micrograms/kg/h)
Number of subjects: 20
Study 6193353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydralazine (0.15 mg/kg)
Number of subjects: 20
Study 31778483 — intervention group
Group type: EXPERIMENTAL
Intervention: X-ray image analysis of seeds with 43% initial water content dried to predetermined levels (43%, 37%, 34%, 31%, and 28%).
Number of subjects: 200
Study 31778483 — intervention group
Group type: EXPERIMENTAL
Intervention: Germination test of seeds after X-ray analysis.
Number of subjects: 200
Study 30724683 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT-T
Number of subjects: 41
Study 30724683 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT-WB
Number of subjects: 41
Study 30724683 — intervention group
Group type: COMPARATOR
Intervention: MICT
Number of subjects: 41
Study 28877914 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation in patients ≤70 years of age
Number of subjects: 1116
Study 28877914 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation in patients >70 years of age
Number of subjects: 1116
Study 28877914 — intervention group
Group type: COMPARATOR
Intervention: Comparison of modes of death between age groups
Number of subjects: 1116
Study 26280945 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoid-rich orange juice (240 ml, 272 mg flavonoids)
Number of subjects: 0
Study 26280945 — intervention group
Group type: COMPARATOR
Intervention: Calorie-matched placebo
Number of subjects: 0
Study 24242903 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 600 µg bid
Number of subjects: 112
Study 24242903 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 1,950 µg bid
Number of subjects: 112
Study 24242903 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (control)
Number of subjects: 112
Study 22886293 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-suction drainage (CSD)
Number of subjects: 65
Study 22886293 — intervention group
Group type: COMPARATOR
Intervention: No wound drainage (NWD)
Number of subjects: 65
Study 21060036 — intervention group
Group type: EXPERIMENTAL
Intervention: ULABTKA cream applied to hands and feet twice per day for 21 days after the start of capecitabine
Number of subjects: 137
Study 21060036 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied to hands and feet twice per day for 21 days after the start of capecitabine
Number of subjects: 137
Study 21060036 — intervention group
Group type: EXPERIMENTAL
Intervention: ULABTKA cream
Number of subjects: 137
Study 21060036 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 137
Study 17353985 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic parastomal hernia repair using a hand‐made 'funnel‐shaped' Gore‐Tex Dual Mesh
Number of subjects: 55
Study 17353985 — intervention group
Group type: COMPARATOR
Intervention: Conversion to laparotomy due to dense adhesions or bowel injury
Number of subjects: 55
Study 16110023 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (25 Gy in 5 days)
Number of subjects: 908
Study 11860727 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual dietary isoflavone intake (high genistein consumption)
Number of subjects: 208
Study 9055051 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric vaccine with lower protein content than adult vaccine; specific dosage not mentioned.
Number of subjects: 0
Study 9055051 — intervention group
Group type: COMPARATOR
Intervention: Adult vaccine (approved); specific dosage not mentioned.
Number of subjects: 0
Study 8419809 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (2.4-16.8 g daily)
Number of subjects: 21
Study 8419809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8419809 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 21
Study 3532292 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nighttime dose of 800 mg cimetidine
Number of subjects: 7
Study 3532292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 29249365 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBS of the affected motor cortex hand area (n=8)
Number of subjects: 21
Study 29249365 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz stimulation of the unaffected motor cortex hand area (n=7)
Number of subjects: 21
Study 29249365 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (n=6)
Number of subjects: 21
Study 27291761 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 60
Study 27291761 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 60
Study 27291761 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 60
Study 25365551 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA/riboflavin corneal collagen cross‐linking (CXL)
Number of subjects: 44
Study 23059922 — intervention group
Group type: EXPERIMENTAL
Intervention: RME/HG group (banded rapid maxillary expander followed by cervical pull headgear)
Number of subjects: 64